Definium Therapeutics (DFTX) Stock Rises as White House Moves on Psychedelic Treatments

TLDR

• Definium Therapeutics publicly backed a new White House Executive Order to accelerate mental health innovation, including psychedelic treatments
• The company is developing DT120 ODT (lysergide tartrate), a proprietary LSD-based formulation, for GAD and MDD
• DT120 has FDA Breakthrough Therapy Designation and four Phase 3 trials underway
• Stifel initiated coverage on April 17 with a Buy rating and a $30 price target, against a current price of ~$22.46
• Insider activity shows no purchases and $0.8M in sales over the past three months

Definium Therapeutics (DFTX) issued a statement on April 19 supporting a newly signed White House Executive Order aimed at speeding up access to psychedelic-based mental health treatments. The stock was up 0.98% on the news.

The Executive Order directs federal agencies to prioritize mental health therapies, streamline regulatory pathways, and expand cross-agency collaboration. It specifically calls out psychedelic medicines as potential tools to address the mental health crisis in the US.

DT120 ODT is Definium’s flagship drug candidate. It is a pharmaceutically optimized formulation of lysergide tartrate — the tartrate salt form of LSD — built using Catalent’s Zydis fast-dissolve technology.

The formulation is designed for faster absorption, better bioavailability, and fewer gastrointestinal side effects compared to standard delivery methods. It acts as a partial agonist at serotonin-2A receptors.

DT120 already holds FDA Breakthrough Therapy Designation. The company currently has four Phase 3 trials running, which will be critical for any future market entry.

Stifel Initiates With Buy, $30 Target

Two days before the White House announcement, on April 17, Stifel initiated coverage of DFTX with a Buy rating and a price target of $30.00. The stock was trading around $22.46 at the time, implying roughly 34% upside to that target.

The initiation reflects growing Wall Street interest in the psychedelic medicine space as regulatory momentum builds.

A Few Cautionary Signals

Not everything points up. Definium’s GF Score stands at just 38 out of 100, with a profitability rank of 1 out of 10 — a reflection of the company’s pre-revenue, clinical-stage status.

Financial strength ranks better at 7 out of 10, suggesting the balance sheet is reasonably stable. Momentum scores a 6, in line with the recent price action.

Insider activity over the last three months tells a mixed story. There have been zero insider purchases, while insiders have sold $0.8 million worth of stock. That kind of one-sided selling doesn’t necessarily signal alarm in a clinical-stage biotech, but it’s worth noting.

The company has a market cap of approximately $2.24 billion.

The White House order aligns with Definium’s existing development roadmap, and the company said it looks forward to continued collaboration with federal agencies, clinicians, and patient communities.

Definium’s DT120 is currently being evaluated for GAD, MDD, and other serious brain health disorders. The company is headquartered in New York and trades on Nasdaq.

The post Definium Therapeutics (DFTX) Stock Rises as White House Moves on Psychedelic Treatments appeared first on CoinCentral.